Article Text

PDF
Republished editorial: Autologous blood products in musculoskeletal medicine
  1. Nicola Maffulli
  1. Professor of Musculoskeletal Disorders, Consultant Orthopaedic Surgeon, Department of Musculoskeletal Disorders, Faculty of Medicine and Surgery, University of Salerno, 84081 Baronissi, Salerno, Italy
  1. Correspondence to
    n.maffulli@qmul.ac.uk

Statistics from Altmetric.com

Although they are trendy money spinners, best evidence shows little effectiveness.

▸ This article is an abridged version of a paper that was published on bmj.com. Cite this article as: BMJ 2013;346:f2979

Participation in almost all sports and physical activities benefits individuals and society as a whole because it promotes health and helps prevent conditions such as osteoporosis, cardiovascular disease, and diabetes; it may also lead to improved mental health. Nevertheless, athletes are highly vulnerable to musculoskeletal injuries, sometimes with devastating effects. Sports injuries cost society billions of dollars in direct and indirect costs. Regenerative medicine technologies, such as autologous blood products for the treatment of tendinopathies, hold the promise of improved outcomes for musculoskeletal conditions that currently have limited or no treatment options. In a linked trial (doi:10.1136/bmj.f2310), Bell and colleagues compare the effectiveness of peritendinous injections of autologous blood with standard eccentric exercise in athletes with Achilles tendinopathy.1

Novel treatments that are reported to accelerate recovery from musculoskeletal injuries, without adversely affecting recurrence rate, are increasingly advocated in the lay media and often heavily promoted to athletes and healthcare professionals.2 …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.